Olaparib (AZD2281) is undergoing evaluation across numerous Phase 1 to Phase 3 clinical trials as monotherapy and in combination with alkylating agents or targeted therapies. Spanning various recruitment statuses from not yet recruiting to completed, these studies focus on malignancies such as triple-negative breast cancer, HRD-positive advanced ovarian carcinoma, prostate cancer, pancreatic cancer, and solid tumors with BRCA or IDH mutations. Research is sponsored by both academic medical institutions and biotechnology enterprises.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03486873 | RECRUITING | Solid Tumors; Hematologic Malignancies |
Merck Sharp & Dohme LLC |
2018-08-21 | PHASE3 |
| NCT06580314 | RECRUITING | Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Ovarian Carcinosarcoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma |
NRG Oncology |
2025-03-12 | PHASE3 |
| NCT06966700 | RECRUITING | Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2025-06-30 | PHASE3 |
| NCT06915025 | RECRUITING | Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma |
Imunon |
2025-07-09 | PHASE3 |
| NCT07486687 | NOT_YET_RECRUITING | Triple Negative Breast Cancer (TNBC), Early Setting; Early Stage Triple-Negative Breast Carcinoma; Triple -Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III |
The Netherlands Cancer Institute |
2026-04 | PHASE3 |
| NCT07647653 | NOT_YET_RECRUITING | Ovarian Cancer |
Shandong University |
2026-06-30 | PHASE2 |
| NCT02813135 | RECRUITING | Pediatric Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2016-08-03 | PHASE1; PHASE2 |
| NCT01042379 | RECRUITING | Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer |
QuantumLeap Healthcare Collaborative |
2010-03-01 | PHASE2 |
| NCT05522491 | NOT_YET_RECRUITING | Solid Tumor |
Hebei Medical University Fourth Hospital |
2026-09-01 | PHASE2 |
| NCT05564377 | RECRUITING | Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2023-04-07 | PHASE2 |
| NCT06712472 | RECRUITING | Endometrial Cancer; p53abn |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-06-26 | PHASE3 |
| NCT05332561 | RECRUITING | Early-stage Breast Cancer |
German Cancer Research Center |
2023-06-29 | PHASE2 |
| NCT07382544 | RECRUITING | Advanced Cancer; Solid Tumor |
M.D. Anderson Cancer Center |
2026-02-12 | PHASE1 |
| NCT05255653 | RECRUITING | Endometrial Cancer |
Leiden University Medical Center |
2021-11-11 | PHASE2; PHASE3 |
| NCT07454018 | NOT_YET_RECRUITING | Recurrent Ovarian Cancer; Platinum-sensitive Ovarian Cancer |
The First Affiliated Hospital of Soochow University |
2026-03-01 | PHASE2 |
| NCT06797635 | RECRUITING | Breast Neoplasms; Breast Cancer |
Merck Sharp & Dohme LLC |
2025-03-20 | PHASE2 |
| NCT06856499 | RECRUITING | Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
University of Colorado, Denver |
2025-12-08 | PHASE1 |
| NCT06976892 | RECRUITING | High Grade Serous Ovarian Cancer |
Institute of Cancer Research, United Kingdom |
2025-08 | PHASE1 |
| NCT06607692 | RECRUITING | Solid Tumor Cancer; Medulloblastoma; High Risk Neuroblastoma; High Grade Gliomas; Meningioma; Paraganglioma; Pheochromocytoma; Neuroendocrine Tumours (NET); Adrenal Tumours; DIPG; Glioblastoma; Glioblastoma (GBM); Osteosarcoma Recurrent; Carcinoma Adrenal; Synovial Sarcomas; Esthesioneuroblastoma; Neuroblastoma Recurrent; Solid Tumor Refractory to Conventional Treatment; Medulloblastoma Recurrent; Paraganglioma/ Phaeochromocytoma; Ependymoma; Ependymoma Recurrent |
Fundación de investigación HM |
2024-09-20 | PHASE1; PHASE2 |
| NCT06245889 | RECRUITING | Triple Negative Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2024-05-01 | PHASE2 |
| NCT05887609 | RECRUITING | Ovary Cancer; Peritoneal Cancer; Fallopian Tube Cancer |
University of Colorado, Denver |
2023-10-03 | PHASE2 |
| NCT06829199 | WITHDRAWN | Early Triple Negative Breast Cancer |
Merck Sharp & Dohme LLC |
2025-03-26 | PHASE2 |
| NCT06353386 | RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Merck Sharp & Dohme LLC |
2024-05-20 | PHASE1; PHASE2 |
| NCT05932862 | RECRUITING | Advanced Solid Tumor |
Exelixis |
2024-04-03 | PHASE1 |
| NCT06201234 | RECRUITING | Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced or Metastatic Breast Cancer; BRCA1 Mutation; BRCA2 Mutation |
GBG Forschungs GmbH |
2024-12-13 | PHASE2 |
| NCT07090369 | NOT_YET_RECRUITING | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
Peter MacCallum Cancer Centre, Australia |
2025-11-01 | PHASE1 |
| NCT07641855 | NOT_YET_RECRUITING | Castration-resistant Prostate Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-09 | PHASE2; PHASE3 |
| NCT06746116 | ACTIVE_NOT_RECRUITING | Advanced or Recurrent Endometrial Cancer |
AstraZeneca |
2024-12-30 | PHASE3 |
| NCT06112379 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2023-11-14 | PHASE3 |
| NCT05952453 | RECRUITING | Ovarian Cancer |
University of Alabama at Birmingham |
2025-02-17 | PHASE2 |
| NCT05554328 | ACTIVE_NOT_RECRUITING | Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2023-04-25 | PHASE2 |
| NCT07371663 | RECRUITING | Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer; Malignant Melanoma |
Beijing Tide Pharmaceutical Co., Ltd |
2025-12-03 | PHASE1; PHASE2 |
| NCT05209529 | WITHDRAWN | TNBC - Triple-Negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation |
European Organisation for Research and Treatment of Cancer - EORTC |
2024-02-01 | PHASE2 |
| NCT07156253 | RECRUITING | Metastatic Solid Tumor; Ovarian Cancer; Breast Cancer; BRCA 1 /2 and / or HRD; Advanced Solid Tumors |
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd |
2025-08-26 | PHASE1 |
| NCT05898399 | RECRUITING | Advanced Solid Tumor; Metastatic Solid Tumor |
Artios Pharma Ltd |
2023-06-30 | PHASE1; PHASE2 |
| NCT05485766 | RECRUITING | Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma |
Okayama University |
2024-07-16 | PHASE2 |
| NCT02208375 | ACTIVE_NOT_RECRUITING | BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Endometrial Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; High Grade Ovarian Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7; Triple-Negative Breast Carcinoma |
M.D. Anderson Cancer Center |
2014-11-11 | PHASE1 |
| NCT07187674 | NOT_YET_RECRUITING | Triple Negative Breast Cancer (TNBC) |
Harbin Medical University |
2025-12-30 | |
| NCT04515836 | RECRUITING | Mesothelioma; Homologous Recombination Deficiency |
University of Chicago |
2021-02-19 | PHASE2 |
| NCT05128734 | NOT_YET_RECRUITING | Breast Cancer Triple Negative |
AHS Cancer Control Alberta |
2026-04-01 | PHASE2 |
| NCT03682289 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Locally Advanced Pancreatic Cancer; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Renal Cell Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Pancreatic Cancer; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Endometrial Cancer; Metastatic Castration-resistant Prostate Cancer |
Rahul Aggarwal |
2019-01-17 | PHASE2 |
| NCT04394858 | ACTIVE_NOT_RECRUITING | Advanced Adrenal Gland Pheochromocytoma; Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8; Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma |
National Cancer Institute (NCI) |
2021-03-17 | PHASE2 |
| NCT04931342 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
Hoffmann-La Roche |
2021-10-07 | PHASE2 |
| NCT07652242 | RECRUITING | Triple Negative Breast Cancer (TNBC) |
Immunomic Therapeutics, Inc. |
2026-06 | PHASE1 |
| NCT06177171 | RECRUITING | BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; PALB2 Gene Mutation; Checkpoint Kinase 2 Gene Mutation; ATM Gene Mutation |
Varun Monga, MBBS |
2024-02-07 | PHASE1 |
| NCT05255471 | RECRUITING | Ovarian Cancer |
National Cancer Institute, Naples |
2022-01-21 | PHASE3 |
| NCT06160843 | RECRUITING | Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma |
National Cancer Centre, Singapore |
2024-07-01 | PHASE2 |
| NCT04644289 | RECRUITING | Epithelial Ovarian Cancer |
AGO Research GmbH |
2022-05-05 | PHASE2 |
| NCT02029001 | RECRUITING | Malignant Solid Neoplasms |
Centre Leon Berard |
2014-03 | PHASE2 |
| NCT07024784 | RECRUITING | Gynecologic Cancers; Platinum-Sensitive Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer (PSOC) |
AbbVie |
2025-07-30 | PHASE2 |
| NCT02693535 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
American Society of Clinical Oncology |
2016-03-14 | PHASE2 |
| NCT04728230 | ACTIVE_NOT_RECRUITING | Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2021-01-05 | PHASE1; PHASE2 |
| NCT04090567 | RECRUITING | Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2020-07-28 | PHASE2 |
| NCT06120972 | WITHDRAWN | Ovarian Cancer |
Alexander B Olawaiye, MD |
2024-01-17 | PHASE2 |
| NCT02489006 | ACTIVE_NOT_RECRUITING | Ovarian Cancer; Fallopian Tube Cancer; Neoadjuvant Treatment; Debulking Surgical Procedures |
University Health Network, Toronto |
2016-07-19 | PHASE2 |
| NCT07667751 | RECRUITING | Ovary Cancer |
Bai-Rong Xia |
2026-06-01 | PHASE2 |
| NCT07407452 | NOT_YET_RECRUITING | Ovarian Cancers |
Jiangsu Cancer Institute & Hospital |
2026-02-01 | PHASE2 |
| NCT05568550 | RECRUITING | Prostate Cancer |
Zin W Myint |
2023-07-27 | PHASE2 |
| NCT07695259 | RECRUITING | Elderly Females; HER2 + Breast Cancer; Neoadjuvant Therapy |
Wen-Ming Cao |
2026-05-25 | PHASE4 |
| NCT05900895 | RECRUITING | Metastatic Breast Cancer |
Mary D Chamberlin |
2024-07-15 | PHASE1 |
| NCT04858334 | RECRUITING | Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma |
National Cancer Institute (NCI) |
2021-06-22 | PHASE2 |
| NCT06217757 | RECRUITING | Lung Cancer; Extensive-stage Small-cell Lung Cancer |
Sichuan University |
2024-04-18 | PHASE1; PHASE2 |
| NCT02484404 | ACTIVE_NOT_RECRUITING | Colorectal Neoplasms; Breast Neoplasms |
National Cancer Institute (NCI) |
2015-06-29 | PHASE1; PHASE2 |
| NCT04624204 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2020-12-08 | PHASE3 |
| NCT02861573 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Merck Sharp & Dohme LLC |
2016-11-17 | PHASE1; PHASE2 |
| NCT06686030 | RECRUITING | Platinum-sensitive Ovarian Cancer |
Akeso |
2025-02-17 | PHASE2 |
| NCT06525298 | RECRUITING | Advanced Solid Tumor; Homologous Recombination Deficiency; HRR Deficiency |
Eisbach Bio GmbH |
2024-09-09 | PHASE1; PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT06298084 | RECRUITING | Breast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-03-21 | PHASE1; PHASE2 |
| NCT04038502 | RECRUITING | Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations |
VA Office of Research and Development |
2019-10-01 | PHASE2 |
| NCT04169841 | ACTIVE_NOT_RECRUITING | Immunotherapy |
Centre Georges Francois Leclerc |
2020-02-10 | PHASE2 |
| NCT05093231 | RECRUITING | Pancreatic Cancer |
Cambridge University Hospitals NHS Foundation Trust |
2025-02-26 | PHASE2 |
| NCT05238922 | ACTIVE_NOT_RECRUITING | Solid Tumors |
Incyte Corporation |
2022-07-05 | PHASE1 |
| NCT05432518 | RECRUITING | Glioblastoma; Recurrent Disease; Recurrent Glioblastoma |
AHS Cancer Control Alberta |
2023-06-27 | EARLY_PHASE1 |
| NCT04086485 | RECRUITING | Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms |
National Cancer Institute (NCI) |
2022-10-03 | PHASE1; PHASE2 |
| NCT05623319 | RECRUITING | SCLC,Extensive Stage |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
2023-03-27 | PHASE2 |
| NCT03085147 | ACTIVE_NOT_RECRUITING | Oral Squamous Cell Carcinoma (OSCC) |
Memorial Sloan Kettering Cancer Center |
2017-03-15 | PHASE1; PHASE2 |
| NCT06116578 | WITHDRAWN | Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-01-01 | PHASE2 |
| NCT06686745 | RECRUITING | Advanced Solid Tumors |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2024-12-06 | PHASE1 |
| NCT03943173 | ACTIVE_NOT_RECRUITING | BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-06-07 | EARLY_PHASE1 |
| NCT04005690 | RECRUITING | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
OHSU Knight Cancer Institute |
2019-08-01 | EARLY_PHASE1 |
| NCT03598257 | ACTIVE_NOT_RECRUITING | Breast Inflammatory Carcinoma |
National Cancer Institute (NCI) |
2019-01-18 | PHASE2 |
| NCT06545942 | RECRUITING | Advanced Solid Tumor; Metastatic Solid Tumor; Prostate Cancer; Pancreas Cancer; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency |
MOMA Therapeutics |
2024-08-13 | PHASE1 |
| NCT07005583 | NOT_YET_RECRUITING | Triple-Negative Breast Cancer (TNBC) |
Tianjin Medical University Cancer Institute and Hospital |
2025-06-30 | PHASE2 |
| NCT04380636 | ACTIVE_NOT_RECRUITING | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2020-07-06 | PHASE3 |
| NCT06488378 | RECRUITING | Breast Cancer; PALB2-Mutated Breast Carcinoma; HER2-negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation |
Dana-Farber Cancer Institute |
2024-08-13 | PHASE1 |
| NCT07460180 | RECRUITING | Ovarian Cancer; Epithelial Cancer; Fallopian Tube Cancer |
The Netherlands Cancer Institute |
2025-05-01 | PHASE1; PHASE2 |
| NCT06909825 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Fusion Pharmaceuticals Inc. |
2025-02-26 | PHASE2 |
| NCT04421963 | ACTIVE_NOT_RECRUITING | Ovarian Cancer; Breast Cancer |
AstraZeneca |
2020-08-04 | PHASE3 |
| NCT07453394 | NOT_YET_RECRUITING | Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC); Endometrial Cancer; Advanced Solid Tumors; Ovarian Cancer |
Qilu Pharmaceutical Co., Ltd. |
2026-04 | PHASE1; PHASE2 |
| NCT07113964 | NOT_YET_RECRUITING | Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency |
The First Affiliated Hospital with Nanjing Medical University |
2025-08-30 | PHASE2 |
| NCT06121401 | ACTIVE_NOT_RECRUITING | Carcinoma, Ovarian Epithelial |
Mario Negri Institute for Pharmacological Research |
2023-09-15 | PHASE4 |
| NCT03786796 | RECRUITING | Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer; Renal Carcinoma; Kidney Cancer Metastatic |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2019-06-03 | PHASE2 |
| NCT07371104 | RECRUITING | Cancer; Ovarian Cancer |
Daewoong Pharmaceutical Co. LTD. |
2026-04-22 | PHASE1 |
| NCT05366166 | ACTIVE_NOT_RECRUITING | Squamous Cell Carcinoma of Head and Neck |
UNC Lineberger Comprehensive Cancer Center |
2022-09-02 | PHASE2 |
| NCT05870423 | RECRUITING | Neuroendocrine Tumors; Peptide Receptor Radionuclide Therapy |
Erasmus Medical Center |
2022-06-01 | PHASE1 |
| NCT03851614 | ACTIVE_NOT_RECRUITING | Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma |
University Health Network, Toronto |
2019-04-08 | PHASE2 |
| NCT04666740 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma; Homologous Recombination Deficiency (HRD) |
Memorial Sloan Kettering Cancer Center |
2020-12-18 | PHASE2 |
| NCT05188508 | RECRUITING | Glioma |
Memorial Sloan Kettering Cancer Center |
2022-01-14 | PHASE2 |
| NCT04683679 | RECRUITING | Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2021-04-21 | PHASE2 |
| NCT04585958 | RECRUITING | Metastatic Malignant Solid Neoplasm; Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2021-05-21 | PHASE1 |
| NCT03579316 | ACTIVE_NOT_RECRUITING | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
M.D. Anderson Cancer Center |
2018-12-07 | PHASE2 |
| NCT03772561 | RECRUITING | Solid Tumor, Adult |
National University Hospital, Singapore |
2018-12-03 | PHASE1 |
| NCT03297606 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
Canadian Cancer Trials Group |
2018-03-23 | PHASE2 |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT03375307 | ACTIVE_NOT_RECRUITING | Advanced Bladder Carcinoma; Advanced Genitourinary System Carcinoma; Metastatic Bladder Carcinoma; Metastatic Genitourinary System Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8 |
National Cancer Institute (NCI) |
2020-11-03 | PHASE2 |
| NCT05807126 | WITHDRAWN | Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
National Cancer Institute (NCI) |
2024-03-05 | PHASE1 |
| NCT03740893 | RECRUITING | Breast Neoplasm; Triple Negative Breast Cancer (TNBC); HRD |
Institute of Cancer Research, United Kingdom |
2019-10-15 | PHASE2 |
| NCT04633239 | RECRUITING | Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma |
National Cancer Institute (NCI) |
2021-07-02 | PHASE1 |
| NCT04548752 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
National Cancer Institute (NCI) |
2021-02-22 | PHASE2 |
| NCT03991832 | ACTIVE_NOT_RECRUITING | Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation |
University Health Network, Toronto |
2019-12-31 | PHASE2 |
| NCT03212742 | ACTIVE_NOT_RECRUITING | Malignant Gliomas; Radiotherapy; PARP Inhibitor |
Centre Francois Baclesse |
2017-09-04 | PHASE1; PHASE2 |
| NCT06419179 | ENROLLING_BY_INVITATION | Small Cell Lung Carcinoma |
University of Cologne |
2024-10-09 | PHASE2 |
| NCT03162627 | ACTIVE_NOT_RECRUITING | Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands |
M.D. Anderson Cancer Center |
2017-08-04 | PHASE1 |
| NCT05411094 | ACTIVE_NOT_RECRUITING | Locally Advanced Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma |
National Cancer Institute (NCI) |
2023-05-22 | PHASE1 |
| NCT04065269 | ACTIVE_NOT_RECRUITING | Gynaecological Cancers |
Institute of Cancer Research, United Kingdom |
2019-11-27 | PHASE2 |
| NCT06441747 | RECRUITING | Cholangiocarcinoma |
Australasian Gastro-Intestinal Trials Group |
2024-09-23 | PHASE2 |
| NCT05498272 | ACTIVE_NOT_RECRUITING | Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer |
Rana McKay, MD |
2023-02-01 | PHASE2 |
| NCT05933265 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancreatic Adenocarcinoma; DDR Gene Mutation |
Lantern Pharma Inc. |
2023-06-09 | PHASE1; PHASE2 |
| NCT04884360 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
AstraZeneca |
2021-05-31 | PHASE3 |
| NCT04753879 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2021-09-29 | PHASE2 |
| NCT05524935 | ACTIVE_NOT_RECRUITING | Uveal Melanoma; Ocular Melanoma |
H. Lee Moffitt Cancer Center and Research Institute |
2022-10-11 | PHASE2 |
| NCT04711824 | ACTIVE_NOT_RECRUITING | Breast Cancer; Brain Metastases, Adult |
Colette Shen |
2022-03-09 | PHASE1; PHASE2 |
| NCT03263650 | COMPLETED | Prostate Cancer Aggressiveness; Prostate Carcinoma |
M.D. Anderson Cancer Center |
2017-10-03 | PHASE2 |
| NCT02849496 | ACTIVE_NOT_RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable Breast Carcinoma; Metastatic Breast Carcinoma |
National Cancer Institute (NCI) |
2017-03-30 | PHASE2 |
| NCT04123366 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2019-11-18 | PHASE2 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT05463848 | ACTIVE_NOT_RECRUITING | Glioblastoma; Recurrent Glioblastoma |
L. Nicolas Gonzalez Castro, MD, PhD |
2022-10-21 | PHASE2 |
| NCT07069335 | RECRUITING | Ovarian Cancer |
Boryung Pharmaceutical Co., Ltd |
2025-06-17 | PHASE1 |
| NCT04748042 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Castrate Sensitive Prostate Cancer; Oligometastatic Disease |
University of Michigan Rogel Cancer Center |
2021-05-28 | PHASE2 |
| NCT04742075 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
2021-12-15 | PHASE2 |
| NCT05482074 | WITHDRAWN | Recurrent Metastatic Melanoma; Cutaneous Melanoma; Mucosal Melanoma; Uveal Melanoma |
Dana-Farber Cancer Institute |
2022-10-04 | PHASE2 |
| NCT06650709 | NOT_YET_RECRUITING | Ovarian Cancer Stage IV |
British Columbia Cancer Agency |
2024-11-01 | PHASE2 |
| NCT04361370 | UNKNOWN | Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer |
Yonsei University |
2020-10-28 | PHASE2 |
| NCT05568212 | RECRUITING | Non-small-cell Lung Cancer Patients |
Fondazione Ricerca Traslazionale |
2022-05-02 | PHASE2 |
| NCT05156268 | COMPLETED | Endometrial Carcinosarcoma |
Memorial Sloan Kettering Cancer Center |
2022-01-27 | PHASE2 |
| NCT04550104 | RECRUITING | Non Small Cell Lung Cancer |
University of Leeds |
2021-03-17 | PHASE1 |
| NCT06482307 | NOT_YET_RECRUITING | Head and Neck Squamous Cell Carcinoma (HNSCC) |
University Medical Center Groningen |
2025-05 | PHASE1; PHASE2 |
| NCT05233982 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2021-12-09 | PHASE2 |
| NCT03594396 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Seoul National University Hospital |
2018-06-29 | PHASE1; PHASE2 |
| NCT05078671 | UNKNOWN | Cancer |
Radboud University Medical Center |
2021-12-15 | PHASE4 |
| NCT04024254 | COMPLETED | Ovarian Cancer; Breast Cancer; Folic Acid Deficiency |
Rush University Medical Center |
2020-07-21 | PHASE4 |
| NCT05629429 | UNKNOWN | Metastatic Breast Cancer |
National Taiwan University Hospital |
2023-02-07 | PHASE2 |
| NCT04592211 | RECRUITING | Gastric Cancer Stage IV |
Yonsei University |
2021-10-01 | PHASE1; PHASE2 |
| NCT05536128 | RECRUITING | Advanced Breast Cancer |
Seoul National University Hospital |
2022-12-31 | PHASE2 |
| NCT05222971 | RECRUITING | Biliary Tract Cancer; DNA Damage Repair Deficiency |
Asan Medical Center |
2022-04-01 | PHASE2 |
| NCT05659914 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Cancer |
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
2022-11-28 | PHASE2 |
| NCT03742245 | ACTIVE_NOT_RECRUITING | Breast Cancer Metastatic; Breast Cancer |
The Methodist Hospital Research Institute |
2019-06-11 | PHASE1 |
| NCT03741426 | UNKNOWN | Renal Cell Cancer |
CCTU- Cancer Theme |
2020-07-27 | PHASE2 |
| NCT05240898 | COMPLETED | Advanced Solid Tumors |
Hoffmann-La Roche |
2021-08-26 | PHASE1 |
| NCT04209686 | COMPLETED | Advanced Gastric Adenocarcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-07-31 | PHASE2 |
| NCT03259503 | COMPLETED | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2019-09-13 | PHASE1 |
| NCT04825990 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Gruppo Oncologico del Nord-Ovest |
2022-03-24 | PHASE2 |
| NCT06437353 | RECRUITING | Ovarian Cancer |
Anhui Provincial Cancer Hospital |
2024-05-25 | PHASE2 |
| NCT06560632 | TERMINATED | Advanced Solid Tumor |
Repare Therapeutics |
2024-09-17 | PHASE1 |
| NCT04643379 | ACTIVE_NOT_RECRUITING | Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma |
Washington University School of Medicine |
2021-08-07 | PHASE2 |
| NCT06331559 | TERMINATED | Advanced Solid Tumors |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2024-03-19 | PHASE1 |
| NCT03742895 | ACTIVE_NOT_RECRUITING | Advanced Solid Neoplasms |
Merck Sharp & Dohme LLC |
2018-12-12 | PHASE2 |
| NCT03685331 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation |
Abramson Cancer Center at Penn Medicine |
2020-10-15 | PHASE1 |
| NCT06078787 | UNKNOWN | Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer |
Azienda Ospedaliero-Universitaria di Modena |
2023-08-01 | PHASE2 |
| NCT03344965 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer; Invasive Breast Cancer; Somatic Mutation Breast Cancer (BRCA1); Somatic Mutation Breast Cancer (BRCA2); CHEK2 Gene Mutation; ATM Gene Mutation; PALB2 Gene Mutation; RAD51 Gene Mutation; BRIP1 Gene Mutation; NBN Gene Mutation |
Beth Israel Deaconess Medical Center |
2018-04-01 | PHASE2 |
| NCT03462342 | COMPLETED | High Grade Serous Carcinoma |
University of Pennsylvania |
2018-03-09 | PHASE2 |
| NCT03568656 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors |
CellCentric Ltd. |
2018-07-23 | PHASE1; PHASE2 |
| NCT05005728 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Xencor, Inc. |
2021-10-22 | PHASE2 |
| NCT04417062 | ACTIVE_NOT_RECRUITING | Osteosarcoma; Osteosarcoma Recurrent |
Dana-Farber Cancer Institute |
2020-11-24 | PHASE2 |
| NCT05320757 | COMPLETED | Endometrial Cancer |
The University of Hong Kong |
2022-04-01 | EARLY_PHASE1 |
| NCT05203445 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2022-01-31 | PHASE2 |
| NCT03874884 | ACTIVE_NOT_RECRUITING | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Peter MacCallum Cancer Centre, Australia |
2019-07-09 | PHASE1 |
| NCT05967286 | WITHDRAWN | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2023-10-23 | PHASE2 |
| NCT03212274 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade 2 Glioma; WHO Grade 3 Glioma |
National Cancer Institute (NCI) |
2019-01-30 | PHASE2 |
| NCT03155620 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor |
National Cancer Institute (NCI) |
2017-07-31 | PHASE2 |
| NCT03317392 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-02-04 | PHASE1; PHASE2 |
| NCT05358639 | ACTIVE_NOT_RECRUITING | High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer |
Sunnybrook Health Sciences Centre |
2022-11-09 | PHASE1 |
| NCT03737643 | ACTIVE_NOT_RECRUITING | Advanced Ovarian Cancer |
AstraZeneca |
2019-01-04 | PHASE3 |
| NCT04042831 | ACTIVE_NOT_RECRUITING | Bile Duct Adenocarcinoma; Fanconi Anemia Complementation Group Gene Mutation; Metastatic Bile Duct Carcinoma; PTEN Gene Deletion |
Academic and Community Cancer Research United |
2020-06-24 | PHASE2 |
| NCT03878095 | ACTIVE_NOT_RECRUITING | Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2020-01-30 | PHASE2 |
| NCT02264678 | ACTIVE_NOT_RECRUITING | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer |
AstraZeneca |
2014-10-31 | PHASE1 |
| NCT04487587 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
The Clatterbridge Cancer Centre NHS Foundation Trust |
2018-10-09 | PHASE2 |
| NCT05949424 | UNKNOWN | Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma |
University Medical Center Groningen |
2024-05 | PHASE4 |
| NCT05379972 | COMPLETED | Gastric Cancer; GastroEsophageal Cancer |
University of Colorado, Denver |
2023-01-12 | PHASE2 |
| NCT04236414 | COMPLETED | Solid Tumours |
AstraZeneca |
2020-01-14 | PHASE1 |
| NCT03532880 | COMPLETED | Small-cell Lung Cancer; Small Cell Lung Carcinoma |
Memorial Sloan Kettering Cancer Center |
2018-07-12 | PHASE1 |
| NCT05340413 | COMPLETED | HER2-negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer |
SOLTI Breast Cancer Research Group |
2022-03-25 | PHASE2 |
| NCT03534453 | COMPLETED | Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive |
AstraZeneca |
2018-05-29 | PHASE3 |
| NCT05033756 | ACTIVE_NOT_RECRUITING | Malignant Neoplasm of Breast; Breast Cancer |
Institut fuer Frauengesundheit |
2022-07-30 | PHASE2 |
| NCT04298021 | UNKNOWN | Bile Duct Cancer; Chemotherapy Effect |
Seoul National University Hospital |
2020-06-25 | PHASE2 |
| NCT04780945 | TERMINATED | Ovarian Neoplasm Epithelial; Homologous Recombination Deficiency; BRCA1 Mutation; BRCA2 Mutation |
Leiden University Medical Center |
2019-01-21 | PHASE2 |
| NCT03579784 | UNKNOWN | Advanced Gastric Cancer |
Do-Youn Oh |
2018-11-26 | PHASE2 |
| NCT03967938 | UNKNOWN | Advanced Cancers Harbouring Mutations in HRG |
Universitair Ziekenhuis Brussel |
2019-02-07 | PHASE2 |
| NCT05286827 | TERMINATED | Pancreatic Acinar Cell Carcinoma |
National Cancer Institute (NCI) |
2023-12-14 | PHASE2 |
| NCT04483544 | TERMINATED | Cervical Cancer; Cervical Carcinoma |
Baptist Health South Florida |
2020-12-03 | PHASE2 |
| NCT03660826 | ACTIVE_NOT_RECRUITING | Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 |
National Cancer Institute (NCI) |
2018-09-27 | PHASE2 |
| NCT05167175 | UNKNOWN | Prostate Cancer; Prostate Carcinoma; Metastatic Prostate Cancer |
Hongqian Guo |
2022-03-01 | PHASE2 |
| NCT05158062 | UNKNOWN | Carcinoma, Ovarian Epithelial |
Kosei Hasegawa, MD, PhD |
2022-04-20 | PHASE2 |
| NCT03838744 | COMPLETED | Advanced Soft Tissue Sarcoma |
Italian Sarcoma Group |
2020-05-20 | PHASE2 |
| NCT05498155 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2022-11-07 | PHASE2 |
| NCT01858168 | COMPLETED | Ewing Sarcoma; Rhabdomyosarcoma |
Massachusetts General Hospital |
2013-07-01 | PHASE1 |
| NCT03782818 | TERMINATED | Pulmonary Arterial Hypertension |
Laval University |
2019-11-20 | PHASE1; PHASE2 |
| NCT03801369 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma |
Gordon Mills, MD, PhD |
2018-12-12 | PHASE2 |
| NCT05457257 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2022-07-29 | PHASE4 |
| NCT05501548 | TERMINATED | Prostate Cancer; Castration-resistant Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-06-30 | PHASE2 |
| NCT03025035 | COMPLETED | Breast Cancer |
Yuan Yuan |
2017-09-10 | PHASE2 |
| NCT02419495 | TERMINATED | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2015-06-26 | PHASE1 |
| NCT03334617 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2017-12-18 | PHASE2 |
| NCT05201612 | UNKNOWN | Metastatic Colorectal Cancer |
Grupo Espanol Multidisciplinario del Cancer Digestivo |
2022-07-07 | PHASE2 |
| NCT05268510 | COMPLETED | Esophagogastric Adenocarcinoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2022-09-15 | PHASE2 |
| NCT03740165 | COMPLETED | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms |
Merck Sharp & Dohme LLC |
2018-12-18 | PHASE3 |
| NCT05432791 | ACTIVE_NOT_RECRUITING | Locally Advanced Uterine Corpus Leiomyosarcoma; Metastatic Uterine Corpus Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Uterine Corpus Leiomyosarcoma |
National Cancer Institute (NCI) |
2023-03-30 | PHASE2; PHASE3 |
| NCT05411679 | WITHDRAWN | Gastric Cancer; Small-cell Lung Cancer |
Ellipses Pharma |
2023-04 | PHASE2 |
| NCT03842228 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2019-11-21 | PHASE1 |
| NCT02810743 | ACTIVE_NOT_RECRUITING | Breast Cancer |
The Netherlands Cancer Institute |
2017-01-25 | PHASE3 |
| NCT05252390 | TERMINATED | Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor |
Nuvation Bio Inc. |
2022-03-29 | PHASE1 |
| NCT04269200 | ACTIVE_NOT_RECRUITING | Endometrial Neoplasms |
AstraZeneca |
2020-05-05 | PHASE3 |
| NCT05128734 | Not yet recruiting | Breast Cancer Triple Negative |
AHS Cancer Control Alberta |
2024-07-01 | Phase 2 |
| NCT04375267 | COMPLETED | Clinical Trial, Phase I; Neuroendocrine Tumors; Thymoma; Mesothelioma |
Vastra Gotaland Region |
2020-04-23 | PHASE1 |
| NCT04336943 | TERMINATED | Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma |
University of Washington |
2021-04-13 | PHASE2 |
| NCT06130254 | TERMINATED | Advanced Solid Tumor; Non-small Cell Lung Cancers |
M.D. Anderson Cancer Center |
2024-01-30 | PHASE1 |
| NCT03150576 | RECRUITING | Breast Cancer |
Cambridge University Hospitals NHS Foundation Trust |
2016-05 | PHASE2; PHASE3 |
| NCT06065059 | TERMINATED | Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer |
Tango Therapeutics, Inc. |
2023-12-08 | PHASE1; PHASE2 |
| NCT05900895 | Not yet recruiting | Metastatic Breast Cancer |
Mary D Chamberlin|Dartmouth-Hitchcock Medical Center |
2024-05 | Phase 1 |
| NCT04826198 | TERMINATED | Ovarian Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2020-10-05 | PHASE1; PHASE2 |
| NCT06377267 | UNKNOWN | Ovarian Cancer |
Vall d'Hebron Institute of Oncology |
2024-02-06 | PHASE2 |
| NCT05262608 | UNKNOWN | Prostate Cancer; Prostate Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-12-07 | PHASE2 |
| NCT03976323 | COMPLETED | Carcinoma, Nonsquamous Non-small-cell Lung |
Merck Sharp & Dohme LLC |
2019-06-28 | PHASE3 |
| NCT06377267 | Recruiting | Ovarian Cancer |
Vall d''Hebron Institute of Oncology |
2024-02-06 | Phase 2 |
| NCT05171816 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2021-06-24 | PHASE3 |
| NCT03953898 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Post Cytotoxic Therapy; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2020-08-04 | PHASE2 |
| NCT03127215 | COMPLETED | Cancers With DNA Repair-Deficiency |
National Center for Tumor Diseases, Heidelberg |
2018-10-25 | PHASE2 |
| NCT03784014 | COMPLETED | Soft Tissue Sarcoma |
Institut National de la Santé Et de la Recherche Médicale, France |
2019-10-19 | PHASE3 |
| NCT05174832 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2022-09-07 | PHASE2 |
| NCT06065059 | Recruiting | Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer|BRCA1 Mutation|BRCA-Mutated Ovarian Carcinoma|BRCA-Associated Breast Carcinoma|HRD Positive Advanced Ovarian Cancer |
Tango Therapeutics Inc. |
2023-12-08 | Phase 1|Phase 2 |
| NCT03278717 | UNKNOWN | Ovarian Cancer |
University College, London |
2018-06-15 | PHASE3 |
| NCT04053322 | ACTIVE_NOT_RECRUITING | ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status |
UNICANCER |
2019-08-26 | PHASE2 |
| NCT05700669 | COMPLETED | Metastatic Castration-resistant Prostate Cancer; Recurrent Epithelial Ovarian Cancer; Breast Cancer |
Valerio Therapeutics |
2023-02-20 | PHASE1; PHASE2 |
| NCT04939662 | COMPLETED | Lung Cancer |
Se-Hoon Lee |
2021-06-11 | PHASE2 |
| NCT05405309 | TERMINATED | Chronic Lymphocytic Leukemia |
University of Utah |
2022-09-23 | PHASE1; PHASE2 |
| NCT03012321 | ACTIVE_NOT_RECRUITING | Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer |
Northwestern University |
2017-01-12 | PHASE2 |
| NCT04951492 | TERMINATED | Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma |
University of Washington |
2022-11-09 | PHASE2 |
| NCT03976362 | COMPLETED | Carcinoma, Squamous Cell, Non-small-cell Lung |
Merck Sharp & Dohme LLC |
2019-06-28 | PHASE3 |
| NCT04091204 | UNKNOWN | BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer |
National Cancer Institute, Naples |
2019-07-04 | PHASE2 |
| NCT05975944 | UNKNOWN | Extensive-stage Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-09 | PHASE1; PHASE2 |
| NCT04614909 | COMPLETED | Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme, Adult |
Nader Sanai |
2021-01-11 | EARLY_PHASE1 |
| NCT04306367 | COMPLETED | Cholangiocarcinoma |
Georgetown University |
2020-04-01 | PHASE2 |
| NCT03810105 | TERMINATED | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2019-03-07 | PHASE2 |
| NCT03008278 | COMPLETED | Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Gastroesophageal Junction Adenocarcinoma; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Unresectable Esophageal Carcinoma; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma |
National Cancer Institute (NCI) |
2018-02-06 | PHASE1; PHASE2 |
| NCT04633902 | UNKNOWN | Metastatic Melanoma |
California Pacific Medical Center Research Institute |
2021-03-03 | PHASE2 |
| NCT04417192 | COMPLETED | Ovarian Cancer |
National Cancer Center Hospital East |
2020-12-01 | PHASE2 |
| NCT03239015 | UNKNOWN | Rare Tumor; Refractory Tumor |
Baodong Qin |
2017-01-01 | PHASE2 |
| NCT04348045 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Adenocarcinoma |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2020-12-07 | PHASE2 |
| NCT02502266 | ACTIVE_NOT_RECRUITING | Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2016-05-03 | PHASE2; PHASE3 |
| NCT03923270 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2019-06-06 | PHASE1 |
| NCT04377087 | TERMINATED | Ovarian Cancer |
Sarah E Taylor |
2020-06-29 | PHASE2 |
| NCT03047135 | ACTIVE_NOT_RECRUITING | Prostate |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2017-03-01 | PHASE2 |
| NCT03745950 | COMPLETED | Endometrial Carcinoma |
ARCAGY/ GINECO GROUP |
2019-02-01 | PHASE2 |
| NCT05245994 | UNKNOWN | Lung Cancer; Small Cell Lung Cancer; Durvalumab |
Li Zhang, MD |
2021-08-21 | PHASE2 |
| NCT04729387 | TERMINATED | Ovarian Cancer |
Novartis Pharmaceuticals |
2021-07-22 | PHASE3 |
| NCT02769962 | TERMINATED | Urothelial Carcinoma; Urothelial Cancer; Lung Neoplasms; Small Cell Lung Cancer; Prostate Cancer |
National Cancer Institute (NCI) |
2016-05-09 | PHASE1; PHASE2 |
| NCT03233204 | COMPLETED | Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor |
National Cancer Institute (NCI) |
2017-09-14 | PHASE2 |
| NCT04456699 | COMPLETED | Metastatic Colorectal Cancer |
Merck Sharp & Dohme LLC |
2020-08-19 | PHASE3 |
| NCT04538378 | TERMINATED | EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine |
National Cancer Institute (NCI) |
2021-07-07 | PHASE2 |
| NCT05295589 | WITHDRAWN | Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma |
National Cancer Institute (NCI) |
2022-06-30 | PHASE2 |
| NCT02893917 | ACTIVE_NOT_RECRUITING | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma With Neuroendocrine Differentiation; Stage IV Prostate Adenocarcinoma AJCC v7 |
National Cancer Institute (NCI) |
2017-08-11 | PHASE2 |
| NCT04566952 | UNKNOWN | Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 Mutation |
Xiaoxiang Chen |
2020-10-28 | PHASE2 |
| NCT04197713 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2020-06-30 | PHASE1 |
| NCT04669002 | COMPLETED | Ovarian Cancer |
Ellipses Pharma |
2020-12-14 | PHASE2 |
| NCT04586335 | TERMINATED | Ovarian Cancer; Breast Cancer; Solid Tumor; Prostate Cancer; Endometrial Cancer |
Haihe Biopharma Co., Ltd. |
2020-09-28 | PHASE1 |
| NCT03498521 | COMPLETED | Cancer of Unknown Primary Site |
Hoffmann-La Roche |
2018-07-10 | PHASE2 |
| NCT03570437 | UNKNOWN | Carcinosarcoma; Endometrial Neoplasms |
University of Manchester |
2018-05-17 | PHASE2 |
| NCT04076579 | COMPLETED | Sarcoma; Sarcoma Metastatic |
University of Michigan Rogel Cancer Center |
2020-03-17 | PHASE2 |
| NCT03787680 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
University of Michigan Rogel Cancer Center |
2019-10-31 | PHASE2 |
| NCT04739800 | ACTIVE_NOT_RECRUITING | Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Mucinous Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tube Undifferentiated Carcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Seromucinous Carcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Ovarian Undifferentiated Carcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Transitional Cell Carcinoma; Recurrent Primary Peritoneal Undifferentiated Carcinoma; Refractory Fallopian Tube Clear Cell Adenocarcinoma; Refractory Fallopian Tube Endometrioid Adenocarcinoma; Refractory Fallopian Tube High Grade Serous Adenocarcinoma; Refractory Fallopian Tube Mucinous Adenocarcinoma; Refractory Fallopian Tube Transitional Cell Carcinoma; Refractory Fallopian Tube Undifferentiated Carcinoma; Refractory Low Grade Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian Endometrioid Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Refractory Ovarian Low Grade Serous Adenocarcinoma; Refractory Ovarian Mucinous Adenocarcinoma; Refractory Ovarian Seromucinous Carcinoma; Refractory Ovarian Transitional Cell Carcinoma; Refractory Ovarian Undifferentiated Carcinoma; Refractory Primary Peritoneal Clear Cell Adenocarcinoma; Refractory Primary Peritoneal Endometrioid Adenocarcinoma; Refractory Primary Peritoneal High Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Transitional Cell Carcinoma; Refractory Primary Peritoneal Undifferentiated Carcinoma |
National Cancer Institute (NCI) |
2021-06-10 | PHASE2 |
| NCT03378297 | COMPLETED | Ovarian Cancer |
Haukeland University Hospital |
2018-05-04 | EARLY_PHASE1 |
| NCT02974621 | ACTIVE_NOT_RECRUITING | Recurrent Glioblastoma |
National Cancer Institute (NCI) |
2017-12-07 | PHASE2 |
| NCT04641728 | UNKNOWN | Cervical Cancer |
Saitama Medical University International Medical Center |
2021-01-01 | PHASE2 |
| NCT04801966 | TERMINATED | Cancer |
Peter MacCallum Cancer Centre, Australia |
2021-09-23 | |
| NCT04191135 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2019-12-19 | PHASE2 |
| NCT03205761 | COMPLETED | Advanced Breast Cancer |
Spanish Breast Cancer Research Group |
2017-10-23 | PHASE2 |
| NCT02299999 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
UNICANCER |
2014-04-07 | PHASE2 |
| NCT02446704 | UNKNOWN | Small Cell Lung Cancer |
Zofia Piotrowska |
2015-10-13 | PHASE1; PHASE2 |
| NCT03182634 | UNKNOWN | Advanced Breast Cancer |
Institute of Cancer Research, United Kingdom |
2016-12-15 | PHASE2 |
| NCT05258747 | COMPLETED | Ovarian Cancer; Breast Cancer |
Sandoz |
2022-04-07 | PHASE1 |
| NCT04330040 | COMPLETED | Ovarian Cancer; Breast Cancer |
AstraZeneca |
2020-05-25 | PHASE4 |
| NCT03699449 | UNKNOWN | Platinum-resistant Recurrent Ovarian Cancer |
Yonsei University |
2018-11-26 | PHASE2 |
| NCT06360445 | COMPLETED | Healthy Participants |
CSPC Ouyi Pharmaceutical Co., Ltd. |
2022-05-26 | PHASE1 |
| NCT03470805 | COMPLETED | Ovarian Cancer |
Grupo Español de Investigación en Cáncer de Ovario |
2018-06-21 | PHASE2 |
| NCT02677038 | COMPLETED | Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7 |
M.D. Anderson Cancer Center |
2016-11-11 | PHASE2 |
| NCT02345265 | ACTIVE_NOT_RECRUITING | Fallopian Tube Carcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma |
National Cancer Institute (NCI) |
2016-05-23 | PHASE2 |
| NCT02498613 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Breast Cancer AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage III Lung Small Cell Carcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Small Cell Carcinoma AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Small Cell Carcinoma AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Small Cell Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma; Unresectable Lung Small Cell Carcinoma; Unresectable Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Unresectable Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2016-08-31 | PHASE2 |
| NCT04556617 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Opna Bio LLC |
2020-09-21 | PHASE1; PHASE2 |
| NCT03434158 | COMPLETED | Prostate Cancer Metastatic |
Spanish Oncology Genito-Urinary Group |
2018-02-06 | PHASE2 |
| NCT03641755 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Dana-Farber Cancer Institute |
2018-10-01 | PHASE1 |
| NCT03834519 | COMPLETED | Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2019-05-02 | PHASE3 |
| NCT03931551 | TERMINATED | Advanced Breast Cancer |
MedSIR |
2019-04-30 | PHASE2 |
| NCT03924245 | TERMINATED | Fallopian Tube Cancer; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Vanderbilt-Ingram Cancer Center |
2020-10-01 | PHASE1 |
| NCT02681237 | COMPLETED | Ovarian Cancer |
University Health Network, Toronto |
2016-04-29 | |
| NCT04166435 | COMPLETED | Colorectal Cancer |
Yale University |
2020-06-17 | PHASE2 |
| NCT02855697 | COMPLETED | Ovarian Cancer |
The Christie NHS Foundation Trust |
2017-05-26 | EARLY_PHASE1 |
| NCT04410887 | UNKNOWN | Stomach Cancer; Gastric Cancer |
Ruijin Hospital |
2020-12 | PHASE1; PHASE2 |
| NCT03561870 | COMPLETED | Recurrent IDH; Mutant High Grade Glioma |
Hospices Civils de Lyon |
2019-03-20 | PHASE2 |
| NCT03286842 | COMPLETED | HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 Mutations |
AstraZeneca |
2018-01-17 | PHASE3 |
| NCT02787642 | COMPLETED | Soft-tissue Sarcoma |
Institut Bergonié |
2016-01 | PHASE1 |
| NCT02734004 | ACTIVE_NOT_RECRUITING | Ovarian; Breast; SCLC; Gastric Cancers |
AstraZeneca |
2016-03-17 | PHASE1; PHASE2 |
| NCT02953457 | COMPLETED | BRCA1 Gene Mutation; BRCA2 Gene Mutation; Ovarian Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Roswell Park Cancer Institute |
2017-06-29 | PHASE2 |
| NCT05860530 | COMPLETED | Neoplasms |
Qilu Pharmaceutical Co., Ltd. |
2021-05-10 | |
| NCT03955640 | TERMINATED | Metastatic Malignant Neoplasm in the Chest Wall; Recurrent Breast Carcinoma |
Thomas Jefferson University |
2019-05-20 | PHASE1 |
| NCT03951415 | UNKNOWN | Endometrial Neoplasms; Uterine Neoplasms; Endometrium Cancer |
Leiden University Medical Center |
2019-07-08 | PHASE2 |
| NCT04034927 | ACTIVE_NOT_RECRUITING | Fallopian Tube Endometrioid Tumor; Fallopian Tube High Grade Serous Adenocarcinoma; Malignant Ovarian Endometrioid Tumor; Ovarian High Grade Serous Adenocarcinoma; Platinum-Sensitive Fallopian Tube Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Platinum-Sensitive Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma |
National Cancer Institute (NCI) |
2019-12-04 | PHASE2 |
| NCT03367689 | TERMINATED | Breast Cancer |
MedSIR |
2018-04-17 | PHASE2 |
| NCT03732820 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2018-10-31 | PHASE3 |
| NCT03448718 | COMPLETED | Metastatic Urothelial Cancer |
Matthew Galsky |
2018-04-17 | PHASE2 |
| NCT02822157 | UNKNOWN | Ovarian Epithelial Cancer |
Universitaire Ziekenhuizen KU Leuven |
2016-08 | PHASE2 |
| NCT03167619 | COMPLETED | Triple Negative Breast Cancer |
Duke University |
2018-10-04 | PHASE2 |
| NCT02511223 | COMPLETED | Pancreatic Cancer |
Sheba Medical Center |
2016-07 | PHASE2 |
| NCT03314740 | COMPLETED | Ovarian Neoplasms |
Mario Negri Institute for Pharmacological Research |
2017-06-12 | PHASE2 |
| NCT03117933 | COMPLETED | Ovarian Cancer |
University of Oxford |
2017-03-09 | PHASE2 |
| NCT03516812 | COMPLETED | Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma |
University of Washington |
2018-08-29 | PHASE2 |
| NCT03205176 | COMPLETED | Malignant Solid Tumors; Lymphoma; Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer |
AstraZeneca |
2017-06-30 | PHASE1 |
| NCT04579133 | TERMINATED | Bladder Cancer; Urothelial Carcinoma |
Latin American Cooperative Oncology Group |
2021-03-01 | PHASE2 |
| NCT03106987 | COMPLETED | Epithelial Ovarian Cancer |
AstraZeneca |
2017-06-08 | PHASE3 |
| NCT03829345 | UNKNOWN | Oesophageal Cancer; Gastro-Oesophageal Junction Cancer; Gastric Cancer |
Royal Marsden NHS Foundation Trust |
2019-07-02 | PHASE2 |
| NCT04239014 | WITHDRAWN | Ovarian Cancer |
AstraZeneca |
2020-08-07 | PHASE2 |
| NCT03022409 | COMPLETED | Head and Neck Squamous Cell Carcinoma |
AstraZeneca |
2017-09-18 | PHASE1 |
| NCT03428607 | COMPLETED | SCLC |
Samsung Medical Center |
2018-10-17 | PHASE2 |
| NCT03775486 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer NSCLC |
AstraZeneca |
2018-12-21 | PHASE2 |
| NCT03009682 | COMPLETED | Small Cell Lung Cancer |
Samsung Medical Center |
2016-08 | PHASE2 |
| NCT02679963 | TERMINATED | Non Small Cell Lung Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2016-02-05 | PHASE2 |
| NCT03432897 | TERMINATED | Prostate Cancer; Adenocarcinoma of the Prostate |
Brown University |
2018-05-25 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT02983799 | COMPLETED | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity |
AstraZeneca |
2016-12-22 | PHASE2 |
| NCT02571725 | ACTIVE_NOT_RECRUITING | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms |
New Mexico Cancer Research Alliance |
2016-02-23 | PHASE1; PHASE2 |
| NCT04261465 | UNKNOWN | High Grade Serous Ovarian Cancer |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2019-12-01 | PHASE2 |
| NCT03330847 | ACTIVE_NOT_RECRUITING | Metastatic Triple Negative Breast Cancer |
AstraZeneca |
2018-03-07 | PHASE2 |
| NCT03459846 | ACTIVE_NOT_RECRUITING | Urinary Bladder Neoplasms |
AstraZeneca |
2018-03-16 | PHASE2 |
| NCT03402841 | COMPLETED | Non-Germline BRCA Mutated Ovarian Cancer |
AstraZeneca |
2018-01-30 | PHASE3 |
| NCT02121990 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
Memorial Sloan Kettering Cancer Center |
2014-04-21 | PHASE1 |
| NCT03880019 | ACTIVE_NOT_RECRUITING | Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Uterine Corpus Leiomyosarcoma |
National Cancer Institute (NCI) |
2019-08-19 | PHASE2 |
| NCT02898207 | COMPLETED | Metastatic High Grade Fallopian Tube Serous Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Primary Peritoneal Serous Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Breast Carcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Triple-Negative Breast Carcinoma; Refractory Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Serous Adenocarcinoma; Refractory Primary Peritoneal Serous Adenocarcinoma; Refractory Triple-Negative Breast Carcinoma; Unresectable High Grade Fallopian Tube Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Primary Peritoneal Serous Adenocarcinoma |
National Cancer Institute (NCI) |
2017-05-19 | PHASE1 |
| NCT04015739 | UNKNOWN | Epithelial Ovarian Cancer; Relapse |
ARCAGY/ GINECO GROUP |
2019-03-01 | PHASE2 |
| NCT02937818 | COMPLETED | Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma |
AstraZeneca |
2016-11-28 | PHASE2 |
| NCT02624973 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Haukeland University Hospital |
2016-04-15 | PHASE2 |
| NCT02308072 | COMPLETED | Head and Neck Cancer |
University College, London |
2015-09 | PHASE1 |
| NCT02476968 | COMPLETED | BRCA or HRR+ Mutated Ovarian Cancer Patients |
AstraZeneca |
2015-09-28 | PHASE4 |
| NCT02032823 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2014-04-22 | PHASE3 |
| NCT02546661 | ACTIVE_NOT_RECRUITING | Muscle Invasive Bladder Cancer |
AstraZeneca |
2016-12-28 | PHASE1 |
| NCT02899728 | TERMINATED | Extensive Stage Lung Small Cell Carcinoma |
National Cancer Institute (NCI) |
2018-03-30 | PHASE2 |
| NCT03534492 | COMPLETED | Bladder Cancer |
Spanish Oncology Genito-Urinary Group |
2018-11-16 | PHASE2 |
| NCT02485990 | TERMINATED | Primary Peritoneal Carcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2016-01-08 | PHASE1 |
| NCT03057145 | COMPLETED | Solid Tumor |
Geoffrey Shapiro, MD, PhD |
2017-03-10 | PHASE1 |
| NCT02446600 | ACTIVE_NOT_RECRUITING | Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2016-03-28 | PHASE3 |
| NCT03109080 | COMPLETED | Breast Neoplasms, Triple-Negative; Breast Neoplasm Malignant Female; Radiotherapy Side Effect |
Institut Curie |
2017-07-24 | PHASE1 |
| NCT03161132 | COMPLETED | Advanced Ovarian Cancer |
Grupo Español de Investigación en Cáncer de Ovario |
2017-12-13 | PHASE2 |
| NCT02229656 | UNKNOWN | Laryngeal Cancer Stage II; Laryngeal Cancer Stage III; Carcinoma, Squamous Cell; Head and Neck Neoplasms |
The Netherlands Cancer Institute |
2014-09-24 | PHASE1 |
| NCT03531840 | COMPLETED | Mesothelioma |
National Cancer Institute (NCI) |
2018-07-11 | PHASE2 |
| NCT03251872 | TERMINATED | Pulmonary Arterial Hypertension |
Laval University |
2018-10-25 | EARLY_PHASE1 |
| NCT02398058 | COMPLETED | Soft Tissue Sarcoma; Bone Tumor |
Italian Sarcoma Group |
2014-07-20 | PHASE1 |
| NCT02882308 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
Hellenic Cooperative Oncology Group |
2016-10-20 | PHASE2 |
| NCT02576444 | TERMINATED | Cancer |
Joseph Paul Eder |
2015-11 | PHASE2 |
| NCT02588105 | COMPLETED | Advanced Solid Tumours |
AstraZeneca |
2015-11-10 | PHASE1 |
| NCT02227082 | COMPLETED | Locally Advanced Malignant Neoplasm; Inflammatory Breast Carcinoma; Triple-Negative Invasive Breast Carcinoma |
The Netherlands Cancer Institute |
2013-10-21 | PHASE1 |
| NCT02889900 | COMPLETED | Recurrent Platinum Resistant Ovarian Cancer |
AstraZeneca |
2017-01-17 | PHASE2 |
| NCT02684318 | UNKNOWN | Advanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer |
Poveda, Andrés, M.D. |
2015-07 | PHASE1; PHASE2 |
| NCT02987543 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2017-02-06 | PHASE3 |
| NCT02392676 | WITHDRAWN | Platinum Sensitive Relapsed Ovarian Cancer |
AstraZeneca |
2016-07 | PHASE3 |
| NCT03570476 | TERMINATED | Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8 |
University of Washington |
2018-09-11 | PHASE2 |
| NCT03575078 | WITHDRAWN | Lymphoma |
University of Texas Southwestern Medical Center |
2018-06-25 | PHASE1 |
| NCT02324998 | COMPLETED | Prostate Cancer |
Cambridge University Hospitals NHS Foundation Trust |
2016-12 | PHASE1 |
| NCT01623349 | COMPLETED | Ovarian Cancer; Breast Cancer |
Dana-Farber Cancer Institute |
2012-09 | PHASE1 |
| NCT01562210 | COMPLETED | NSCLC |
The Netherlands Cancer Institute |
2012-04 | PHASE1 |
| NCT02511795 | COMPLETED | Refractory Solid Tumours; Relapsed Small Cell Lung Cancer (SCLC) |
AstraZeneca |
2015-08-06 | PHASE1 |
| NCT02477644 | COMPLETED | Ovarian Cancer |
Arcagy Research |
2015-05-06 | PHASE3 |
| NCT03553108 | COMPLETED | Malignant Solid Tumor |
AstraZeneca |
2018-05-16 | PHASE1 |
| NCT01682772 | UNKNOWN | Adenocarcinoma of the Prostate |
Institute of Cancer Research, United Kingdom |
2012-07 | PHASE2 |
| NCT02789332 | COMPLETED | Breast Cancer; Triple Negative Breast Neoplasms; HRpos Breast Neoplasms; BRCA 1 /2 and / or HRD |
GBG Forschungs GmbH |
2016-09 | PHASE2 |
| NCT02184195 | COMPLETED | Germline BRCA1/2 Mutations and; Metastatic Adenocarcinoma of the Pancreas |
AstraZeneca |
2014-12-16 | PHASE3 |
| NCT02418624 | COMPLETED | Breast Cancer; Ovarian Cancer; Advanced Cancer |
The Netherlands Cancer Institute |
2015-05 | PHASE1 |
| NCT02686008 | WITHDRAWN | Squamous Cell Carcinoma of the Head and Neck |
Yale University |
2018-01 | PHASE1 |
| NCT02117167 | COMPLETED | Non-small Cell Lung Cancer Metastatic |
UNICANCER |
2014-04-23 | PHASE2 |
| NCT01788332 | UNKNOWN | Non-small Cell Lung Cancer |
Lisette Nixon |
2014-01 | PHASE2 |
| NCT01650376 | UNKNOWN | Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Uterine Cancer |
Swedish Medical Center |
2012-08 | PHASE1; PHASE2 |
| NCT02755844 | COMPLETED | Recurrent Endometrial Cancer |
Hospices Civils de Lyon |
2016-09-23 | PHASE1; PHASE2 |
| NCT01116648 | ACTIVE_NOT_RECRUITING | Fallopian Tube Carcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2010-04-14 | PHASE1; PHASE2 |
| NCT02282020 | COMPLETED | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity |
AstraZeneca |
2015-02-06 | PHASE3 |
| NCT02533765 | COMPLETED | Neoplasms, Germ Cell and Embryonal |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
2015-09-11 | PHASE2 |
| NCT03544125 | COMPLETED | Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
OHSU Knight Cancer Institute |
2018-05-03 | PHASE1 |
| NCT02340611 | COMPLETED | Ovarian Cancer |
University Health Network, Toronto |
2015-06 | PHASE2 |
| NCT01844986 | ACTIVE_NOT_RECRUITING | Newly Diagnosed; Advanced Ovarian Cancer; FIGO Stage III-IV; BRCA Mutation; Complete Response; Partial Response; First Line Platinum Chemotherapy |
AstraZeneca |
2013-08-26 | PHASE3 |
| NCT02681562 | UNKNOWN | Breast Cancer; Triple Negative Breast Cancer |
Istituti Ospitalieri di Cremona |
2016-01 | PHASE2 |
| NCT01972217 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2014-04-01 | PHASE2 |
| NCT01390571 | COMPLETED | Brain and Central Nervous System Tumors |
Cancer Research UK |
2011-07 | PHASE1 |
| NCT02000622 | COMPLETED | Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation |
AstraZeneca |
2014-03-27 | PHASE3 |
| NCT01758731 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
University of Colorado, Denver |
2012-10-22 | PHASE1 |
| NCT01894243 | COMPLETED | Solid Tumours |
AstraZeneca |
2014-03-13 | PHASE1 |
| NCT02561832 | TERMINATED | Breast Cancer |
AstraZeneca |
2015-11-06 | PHASE1 |
| NCT01874353 | ACTIVE_NOT_RECRUITING | Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy |
AstraZeneca |
2013-09-03 | PHASE3 |
| NCT01813474 | COMPLETED | Cancer; Advanced Solid Malignancies |
AstraZeneca |
2013-03-25 | PHASE1 |
| NCT02430311 | COMPLETED | Advanced Solid Tumours |
AstraZeneca |
2015-06-10 | PHASE1 |
| NCT01513174 | COMPLETED | Non Small Cell Lung Cancer |
Spanish Lung Cancer Group |
2011-08 | PHASE1; PHASE2 |
| NCT01924533 | COMPLETED | Gastric Cancer |
AstraZeneca |
2013-09-03 | PHASE3 |
| NCT02338622 | COMPLETED | Advanced Cancer |
Royal Marsden NHS Foundation Trust |
2014-03-31 | PHASE1 |
| NCT01460888 | UNKNOWN | Carcinoma of the Oesophagus |
The Christie NHS Foundation Trust |
2013-07 | PHASE1 |
| NCT02093351 | COMPLETED | Solid Tumours |
AstraZeneca |
2014-09-01 | PHASE1 |
| NCT01894256 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-11 | PHASE1 |
| NCT01237067 | COMPLETED | Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer |
National Cancer Institute (NCI) |
2011-02-07 | PHASE1 |
| NCT01445418 | COMPLETED | Breast Cancer; Ovarian Cancer |
National Cancer Institute (NCI) |
2008-05-12 | PHASE1 |
| NCT01929603 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-12 | PHASE1 |
| NCT01921140 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-09-24 | PHASE1 |
| NCT01900028 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-10 | PHASE1 |
| NCT01296763 | COMPLETED | Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2011-01 | PHASE1 |
| NCT01583543 | COMPLETED | Ewing's Sarcoma |
Massachusetts General Hospital |
2012-05 | PHASE2 |
| NCT01851265 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-07-04 | PHASE1 |
| NCT00516724 | COMPLETED | Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel |
AstraZeneca |
2007-06-22 | PHASE1 |
| NCT00535353 | COMPLETED | Colorectal Cancer |
NCIC Clinical Trials Group |
2008-01-02 | PHASE1 |
| NCT01661868 | WITHDRAWN | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer |
Dana-Farber Cancer Institute |
2012-08 | PHASE2 |
| NCT01078662 | COMPLETED | Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours |
AstraZeneca |
2010-02-21 | PHASE2 |
| NCT01063517 | COMPLETED | Gastric Cancer |
AstraZeneca |
2010-02-02 | PHASE2 |
| NCT00912743 | COMPLETED | Colorectal Cancer |
AstraZeneca |
2009-05 | PHASE2 |
| NCT00782574 | COMPLETED | Advanced Solid Tumors |
AstraZeneca |
2008-11-12 | PHASE1 |
| NCT00819221 | TERMINATED | Solid Tumors |
AstraZeneca |
2009-01-05 | PHASE1 |
| NCT01081951 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
AstraZeneca |
2010-02-04 | PHASE2 |
| NCT00515866 | COMPLETED | Pancreatic Neoplasms |
AstraZeneca |
2007-08 | PHASE1 |
| NCT00678132 | COMPLETED | Neoplasms |
National Cancer Institute (NCI) |
2008-04-24 | PHASE1 |
| NCT00753545 | COMPLETED | Ovarian Cancer |
AstraZeneca |
2008-08-28 | PHASE2 |
| NCT00679783 | COMPLETED | Ovarian Carcinoma; Breast Cancer |
AstraZeneca |
2008-07-08 | PHASE2 |
| NCT00707707 | COMPLETED | Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast Cancer |
AstraZeneca |
2008-09-15 | PHASE1 |
| NCT00628251 | COMPLETED | Ovarian Neoplasms |
AstraZeneca |
2008-07-30 | PHASE2 |
| NCT00494442 | COMPLETED | Ovarian Neoplasm |
AstraZeneca |
2007-06-11 | PHASE2 |
| NCT00572364 | COMPLETED | Advanced Solid Malignancies |
AstraZeneca |
2007-11 | PHASE1 |
| NCT00710268 | COMPLETED | Neoplasm Metastasis |
AstraZeneca |
2008-06 | PHASE1 |
| NCT00516438 | COMPLETED | Malignant Solid Tumors |
AstraZeneca |
2007-07 | PHASE1 |
| NCT00494234 | COMPLETED | Breast Neoplasms |
AstraZeneca |
2007-06-15 | PHASE2 |
| NCT00777582 | ACTIVE_NOT_RECRUITING | Solid Tumors |
AstraZeneca |
2008-10-27 | PHASE1 |
| NCT00516802 | COMPLETED | Melanoma Neoplasms |
AstraZeneca |
2007-01 | PHASE1 |
| NCT00516373 | COMPLETED | Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein |
AstraZeneca |
2005-07-11 | PHASE1 |
| NCT00633269 | COMPLETED | Neoplasm Metastasis |
AstraZeneca |
2008-04 | PHASE1 |
| NCT01491139 | WITHDRAWN | Carcinoma, Squamous Cell |
University College, London |
PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
AZD2281 (Olaparib)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- AZD2281 (Olaparib) Mechanism of Action: PARP Inhibition in Homologous Recombination Deficient Cell Research
- AZD2281 (Olaparib): Selectivity & Specificity
- AZD2281 (Olaparib) Working Concentration | Cell Culture | Treatment
- AZD2281 (Olaparib) Solubility in DMSO
- AZD2281 (Olaparib) Stock Solution
- AZD2281 (Olaparib) Storage
- AZD2281 (Olaparib) Stability
- AZD2281 (Olaparib) Combination Database
- AZD2281 (Olaparib) Molecular Weight
- AZD2281 (Olaparib) SMILES
- AZD2281 (Olaparib) CAS Number
- AZD2281 (Olaparib) Chemical Structure (2D and 3D)
- AZD2281 (Olaparib) IC50 for Cell-based and Cell-free Assays
- AZD2281 (Olaparib) Sigma (SML3705)? Try a better option.
- AZD2281 (Olaparib) MedChemExpress (HY-10162)? Try a better option.
- AZD2281 (Olaparib) Cell Signaling Technology (93852)? Try a better option.
- AZD2281 (Olaparib) Abmole (M1664)? Try a better option.
- AZD2281 (Olaparib) Cayman (10621)? Try a better option.
- AZD2281 (Olaparib) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.